Abstracts S393 ( 1010) Marijuana in Pediatric and Adult Congenital Heart Transplant Listing: A Survey of Provider Practices and Attitudes K.A. Phillips , 1 P.T. Thrush, 2 A. Lal, 3 S.J. Kindel, 4 C. Castleberry, 5 J. Sparks, 6 K.P. Daly, 7 J.N. Johnson. 8 1 Mayo Clinic School of Medicine, Rochester, MN; 2 Lurie Children's Hospital of Colorado, Chicago, IL; 3 Primary Children's Hospital, Salt Lake City, UT; 4 Children's Hospital of Wisconsin, Milwaukee, WI; 5 St Louis Children's Hospital, St. Louis, MO; 6 Norton Children's Hospital, Louisville, KY; 7 Boston Children's Hospital, Boston, MA; 8 Mayo Clinic, Rochester, MN. Purpose: Despite increasing legalization and use of marijuana for medical purposes, there is no consensus among pediatric heart transplant institutions or providers regarding users’ eligibility for cardiac transplant. Pediatric heart transplant providers may care for both pediatric and adult congenital heart disease (ACHD) patients. Methods: We sent an anonymous, web-based survey to pediatric and ACHD transplant providers, including physicians, surgeons, transplant coordinators, and pharmacists. Survey questions focused on current institutional policies and personal opinions about marijuana use in patients being considered for heart transplantation. Results: Of the respondents, 84% practice in the U.S. and Canada, with the remaining from Europe (12%), Asia (3%) and South America (1%). Most providers (80%) care for both pediatric and ACHD patients. Respondents included cardiologists (77%), surgeons (11%), with the remaining being coordinators and pharmacists. Most providers (73%) reported their institu- tion had no policy regarding marijuana use in heart transplant candidates. The mode of consumption is considered in listing decisions by 18% of institutions, with 87% and 53% approving of oral and transdermal routes respectively and only 7% approving of vaporized or smoked routes. While 73% of providers would consider illegal marijuana use an absolute/relative contraindication to heart transplant listing, the number decreases to 57% for legal recreational users and 21% for legal medical users. There were no significant differences in responses between centers that transplant ACHD patients and those who did not. Most providers personally believe marijuana to be physically and mentally/emotionally harmful to pediatric patients (68% and 73% respectively). Conclusion: Many institutions lack a policy regarding marijuana use in pedi- atric and ACHD heart transplant listing candidates, and there is considerable disagreement among providers on the best practice. With increasing legali- zation and use of marijuana, each institution will have to address this issue thoughtfully to continue to provide high-quality, consistent, and equitable care for pediatric and ACHD transplant candidates. ( 1011) Outcomes of Myocarditis in Patients with Normal Left Ventricular Systolic Function on Admission S.B. Barfuss , 1 S.R. Deshpande, 2 R.J. Butts, 3 K.R. Knecht, 4 M.E. Richmond, 5 K. Gambetta, 6 A.K. Lal. 7 1 Pediatrics, Primary Children's Hospital, University of Utah, Salt Lake City, UT; 2 Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA; 3 Pediatric Cardiology, Children's Health, UT Southwestern Medical Center, Dallas, TX; 4 Pediatric Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR; 5 Pediatric Cardiology, Columbia University Medical Center, New York, NY; 6 Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; 7 Pediatric Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT. Purpose: The objective of this study was to describe a cohort of patients with clinical myocarditis and normal left ventricular (LV) systolic function. Methods: A retrospective chart review was performed at 7 tertiary pediatric hospitals. Local electronic medical records were searched between 2008- 2012 for patients ≤ 18 years admitted with an ICD-9 code consistent with myocarditis. Patients were excluded if admission LV systolic ejection frac- tion (EF) < 50%, fractional shortening (FS) <28% or if the admitting or consulting cardiologist did not suspect myocarditis during the hospitalization. Results: Of the 171 patients identified with myocarditis, 75 patients had normal LV function on admission. Median age was 15.5 years (IQR 13.6- 16.6), 33% were female, and 39% were non-Caucasian. Patients presented Conclusion: This pilot study confirmed successful transition with good reten- tion of a cohort of young adult HT pts. Although our educational intervention may be efficacious at 3 months for some pt outcomes (i.e., tacro levels), at 6 months follow-up, no differences were detected between groups for any outcomes. Extension of the intervention period after transfer may be needed. More study is warranted in a larger randomized controlled trial. ( 1009) Practice Variation in Detection of Coronary Allograft Vasculopathy (CAV) in Children: A Pediatric Heart Transplant Study E. Pahl , 1 D. Nandi, 2 J. Vo, 3 K. Schumacher, 4 M. Fenton, 5 R. Singh, 6 K. Lin, 7 J. Conway, 8 E. Pruitt, 3 S. Dahl, 9 J.M. Lamour, 10 J. Kirklin, 3 C. Chin. 11 1 Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern, Chicago, IL; 2 Cardiology, Nationwide Children's Hospital (CCO), Columbus, OH; 3 Cardiology, University of Alabama at Birmingham (UAB), Birmingham, AL; 4 Cardiology, University of Michigan, CS Mott Children’s Hospital (MCH), Ann Arbor, MI; 5 Cardiology, Great Ormond Street Hospital for Children (GOS), London, United Kingdom; 6 Cardiology, UC San Diego, Rady Children's Hospital (RCH), San Diego, CA; 7 Cardiology, The Children's Hospital of Philadelphia (CPH), Philadelphia, PA; 8 Cardiology, University of Alberta (UOA), Edmonton, AB, Canada; 9 Cardiology, Mayo Clinic (MCR), Rochester, MN; 10 Cardiology, The Children’s Hospital at Montefiore (MMC), Bronx, NY; 11 Cardiology, Cincinnati Children's Hospital Medical Center (CCH), Cincinnati, OH. Purpose: CAV is a leading cause of mortality after heart transplantation (HT). We reviewed surveillance frequency & methodology for CAV at PHTS sites to assess practice variation. Methods: Coronary evaluation practices were reviewed among 48 PHTS centers 2001 to 2016 for primary HT, 2001- 2015. Coronary surveillance was categorized as non-invasive or invasive, and patient (pt) angiographies (angio) s were categorized as surveillance or for new symptoms. CAV detection rate in each category was calculated for each year of follow up. Results: Angio comprised 97% of all coronary evaluation, with 11,674 angios in 3,007 unique pts. Figure depicts % pts who had angio each yr, and % CAV detected. While 60% of sites evaluate by angio only, 40% also performed non-invasive tests. Two sites used non-invasive tests only in > 20% of their pts. The majority of angios were done for surveillance every 1-2 years; only 2% of pts had angios based on new symptoms and 1% of all pts (0.6% of all evaluations) did not receive any surveillance angio. Non-invasive surveillance methods varied widely by site, but overall, included resting echocardiography (echo)-55%, dobutamine stress echo (37%), CT angio (1.3%), exercise stress test (1%), exercise stress echo (2%), and stress perfusion testing (0.33%). Ten year freedom from CAV for 1 year survivors overall was excellent at 92%. When stratified by age of HT recipient, infants survival was superior at 95% compared to 86% for children > 10yrs at time of HT (P<0.01). Once CAV develops, however, graft survival was 44% after 5 yrs. Conclusion: Angiography predominates for CAV surveillance in pedi- atric HT recipients, with angio frequency at 1-2 years, although many sites use other non-invasive tests to augment screening. Freedom from CAV remains high across age groups but once detected, graft loss was significant. Greater understanding of practice variation in prophylaxis and treatment may aid in standardizing approaches to CAV management in the pediatric population.